ArticleGene therapy2000
Quantitation of HSV mass distribution in a rodent brain tumor model.
Article in Gene therapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Quantitative Whole-Body Imaging of I-124-Labeled Adeno-Associated Viral Vector Biodistribution in Nonhuman Primates.Human gene therapy · 2020Article
- Radioiodinated Capsids Facilitate In Vivo Non-Invasive Tracking of Adeno-Associated Gene Transfer Vectors.Scientific reports · 2017Article
- Expression of inhibitor of growth 4 by HSV1716 improves oncolytic potency and enhances efficacy.Cancer gene therapy · 2012Article
- Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery.Cancer gene therapy · 2011Article
- HSV Recombinant Vectors for Gene Therapy.The open virology journal · 2010Article
- Bystander or no bystander for gene directed enzyme prodrug therapy.Molecules (Basel, Switzerland) · 2009Review
- (Strept)avidin-displaying lentiviruses as versatile tools for targeting and dual imaging of gene delivery.Gene therapy · 2009Article
- Plasma clearance of bacteriophage Qbeta particles as a function of surface charge.Journal of the American Chemical Society · 2008Article
- Non-invasive genetic imaging for molecular and cell therapies of cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2007Review
- SPECT/CT imaging of baculovirus biodistribution in rat.Gene therapy · 2007Article
- Gene expression and gene therapy imaging.European radiology · 2007Review
- The status of gene therapy for brain tumors.Expert opinion on biological therapy · 2007Review
- Magnetic resonance imaging of viral particle biodistribution in vivo.Gene therapy · 2006Article
- Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain.Gene therapy · 2005Article
- Chemically inactivated adenoviral vectors that can efficiently transduce target cells when delivered in the form of virus-microbead conjugates.Gene therapy · 2005Article
- Molecular imaging of gene therapy for cancer.Gene therapy · 2004Review
- Gene therapy progress and prospects: noninvasive imaging of gene therapy in living subjects.Gene therapy · 2004Review
- Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells.Gene therapy · 2003Review
- Conditionally replicating viruses in cancer therapy.Gene therapy · 2003Article
- Oncolytic viruses.Nature reviews. Cancer · 2002Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
A number of different viral vectors have been used for gene therapy of tumors, with many more under construction, ultimately designed to improve tumor targeting and transduction efficiency. It has become apparent that insufficient viral delivery can be a key limitation to treatment efficacy. We have studied the in vivo mass distribution of a herpes simplex virus type 1 (HSV) vector, hrR3, by radiolabeling it with 111In-oxine. The virus was administered to intracerebral 9L glioma bearing Fisher (F-344) rats by intracarotid and intratumoral injection. The blood half-life of the virus was 1 min (fast component, 10% contribution) and 180 min (slow component, 90% contribution). Approximately 20% of activity had been excreted by 24 h. With intracarotid injection, the total amount of virus that accumulated in tumor was 0.10+/-0.07% of the injected dose (ID)/g at 1 h and 0.19+/-0.01% ID/g at 24 h. By comparison, co-injection of RMP-7, a synthetic bradykinin analog, with the virus, resulted in slightly increased tumor delivery of 0.17+/-0.10% ID/g (P 0.05) at 1 h. The 1 h organ distribution after intra-arterial injection (%ID/organ) was as follows: liver 273+/-2.86%, lung 2.10+/-0.68% and kidney 1.78+/-1.60% with lesser amounts in other organs. When virus was injected directly into the tumor, 71% of virus remained in tumor at 24 h (590+/-212 %ID/g, consistent with the small tumor mass containing most of the virus) with the following distribution regions: tumor > border zone > normal brain (99:40: 1). These studies are the first quantitative mass distribution studies of HSV vectors in an experimental brain tumor model. Localization and quantitation of viral accumulation in vivo will enable detailed analysis of viral and organ interactions critical for advancing the therapeutic use of vectors.
Indexed as
Identifiers
11083473What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.